also demonstrated the administration of larotrectinib has resulted in the successful management for remission at 6 months in a high-grade glioneuronal tumor harboring the MEF2D-NTRK1 fusion (43). This evidence concerns the gene NTRK1 and mixed neuronal-glial tumor.